Yeah, i think the guidance will be the key driver going forward. Musclepharm has a bad record of underestimating earnings going forward...which is a negative (even if better than overestimating).
A positive guidance and the stock could pop to $20...a highly conservative, understating guidance and the stock could tank.
News 
Market Data 
Discover 
